Aladdin Healthcare Technologies SE

  • WKN: A12ULL
  • ISIN: DE000A12ULL2
  • Land: Deutschland

Nachricht vom 28.07.2020 | 09:00

Aladdin Healthcare Technologies becomes a sponsor of University College London's (UCL) Industry Exchange Network (IXN) Programme

DGAP-News: Aladdin Healthcare Technologies SE / Key word(s): Miscellaneous
28.07.2020 / 09:00
The issuer is solely responsible for the content of this announcement.

Aladdin Healthcare Technologies becomes a sponsor of University College London's (UCL) Industry Exchange Network (IXN) Programme

BERLIN/LONDON, July 28, 2020 - Aladdin Healthcare Technologies SE ("Aladdin", ISIN: DE000A12ULL2), a leading developer of Artificial Intelligence (AI) based healthcare diagnostics and drug discovery applications, was appointed last week as an official sponsor of the University College London's (UCL) Industry Exchange Network (IXN) programme.

This partnership enables Aladdin to work closely with the Computer Science department of UCL and to work with gifted graduate students from one of the world's leading universities. Other sponsors in the same IXN programme include global industry leaders such as DeepMind, IBM, Facebook, Amazon, JP Morgan. UCL is home to some of the most influential and creative researchers in the field of Computer Science. The Computer Science department of UCL has made a deep and lasting impact on all aspects of society, from medical image analysis to deep learning development and was ranked amongst the top 20 in the world, according to Times Higher Education (THE) in 2019.

UCL's sponsorship programme aims to build close relationships with companies that share the ambition to create and develop an innovative and diverse learning experience for the students. In addition to this UCL aims to meet the business objectives of the sponsors, providing return on investment, increased brand awareness and influence amongst the students and academics, and most importantly a positive partnership experience with the UCL Computer Science Department.

Wade Menpes-Smith, CEO of Aladdin Healthcare Technologies SE, comments: "This summer Aladdin has taken on 4 leading master students as interns from more than 40 applicants from UCL and Imperial College London. 3 of the students have previous degrees from Oxford University and Cambridge University, another one holds a bachelor degree from the University of Edinburgh. This shows Aladdin is setting a high standard on recruiting and aiming to build the best-in-class team, which consists of both senior AI award winners and passionate juniors."
 

About Aladdin Healthcare Technologies SE
Aladdin Healthcare Technologies SE (and its wholly owned subsidiary Aladdin Healthcare Technologies Ltd.) is a leading developer of AI healthcare diagnostics and drug discovery applications that can accelerate both early stage disease diagnosis and the end-to-end drug discovery process. Aladdin targets age-related diseases including a significant focus on Alzheimer's disease. Aladdin accomplishes this by collaborating with numerous partners within the global healthcare ecosystem to confidentially and securely gather targeted data including, genome, tabular, MRI, PET, cognition and other lifestyle data. These datasets are then analysed by our award-winning AI team and used to develop proprietary AI tools that can assist healthcare professionals to more accurately and efficiently diagnose age-related diseases. This new diagnostic process will save significant time and costs for healthcare professionals. Additionally, our AI drug discovery platform will be used by pharmaceutical Companies to speed up drug development, clinical trials and predict outcomes more accurately.

Website Link: www.aladdinid.com
GSIN: A12ULL
ISIN: DE000A12ULL2
TICKER SYMBOL: NMI

For further information:

Aladdin Healthcare Technologies Ltd.

24-26 Baltic Street West
London EC1Y 0UR
Phone +44 7714 719696
Email: info@aladdinid.com

Contact Press
CROSS ALLIANCE communication GmbH
Sara Pinto
Phone +49 89 1250 90330
Email: pi@crossalliance.de
www.crossalliance.de



28.07.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

Event im Fokus

Termine 2021

10. Juni 2021:Fachkonferenz Immobilien

14./15. Juli 2021: Fachkonferenzen Beteiligungsgesellschaften & Consumer/Leisure

13./14. Oktober 2021: Fachkonferenzen Finanzdienstleistungen/Technologie

10./11. November 2021: Fachkonferenzen Software/IT & Branchenmix

„Je nach aktueller Covid-19 Situation und den bestehenden Vorschriften für Versammlungen entscheidet sich ca. 5 Wochen vor dem Termin, in welcher Form die Konferenzen stattfinden.“

GBC-Fokusbox

Kaufen: Aspermont Limited hat Turnaround abgeschlossen

Aspermont Limited ist der weltweit führende Anbieter von Business-to-Business-Medien (B2B) für den Rohstoffsektor. Mit einem neuen Management hat das Unternehmen seit 2016 den erfolgreichen Turnaround von einem traditionellen Medienunternehmen zu einem digitalen B2B-XaaS-Geschäftsmodell umgesetzt. Das Unternehmen hat diesen Turnaround im GJ 2020 abgeschlossen, als es sein erstes positives EBITDA-Ergebnis verzeichnete. Auf der Grundlage unseres DCF-Modells haben wir ein Kursziel von 0,09 AUD (0,06 Euro) pro Aktie ermittelt und vergeben das Rating KAUFEN.

News im Fokus

Vonovia SE: Deutschlands führendes Wohnungsunternehmen baut erneuerbare Energie weiter aus: Vonovia bestückt 30.000 Dächer mit Photovoltaik-Anlagen

21. September 2021, 09:58

Aktueller Webcast

Stealth BioTherapeutics

Cantor Global Healthcare Conference Fireside Chat

30. September 2021

Aktuelle Research-Studie

q.beyond AG

Original-Research: q.beyond AG (von Montega AG): Kaufen

21. September 2021